MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNTZhan Zhang, Carla Grandori, Hong Sun et al.|Cell Cycle|2009Cited by 284
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancerGoldie Y.L. Lui, Carla Grandori, Reid Shaw et al.|EBioMedicine|2020Cited by 38
Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell CarcinomaShogo Shigeta, Christopher J. Kemp, Goldie Y.L. Lui et al.|Molecular Cancer Therapeutics|2021Cited by 30
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testingHeidi J. Gray, Carla Grandori, Payel Chatterjee et al.|npj Precision Oncology|2023Cited by 26
Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck CancerChang Xu, Eduardo Méndez, Olga Nikolova et al.|Clinical Cancer Research|2018Cited by 25